CYCC Earnings Prediction
The chart below shows how CYCC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CYCC sees a +13.12% change in stock price 10 days leading up to the earnings, and a -12.55% change 10 days following the report. On the earnings day itself, the stock moves by -1.26%. This data can give you a slight idea of what to expect for the next quarter's release.
CYCC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
4.00K
-98.93%
-86.21%
Gross Margin
--
--
--
Operating Margin
-91100.00%
5631.22%
506.64%
Net Margin
-81425.00%
5474.80%
701.54%
EPS
-0.72
-89.04%
-68.28%
No Data Available
CYCC Earnings Analysis
Cyclacel Pharmaceuticals, Inc Corporation (CYCC.O) Earnings Conference Call
Positive
Progress with the precision medicine strategy for Fadraciclib (Fadra) is going well, with recruitment in the enriched cohort of the Phase 2 proof-of-concept study ongoing.
Evidence from preclinical data and Phase 1 clinical results presented at ASCO showed clinical benefit in heavily pre-treated patients with various tumor types, indicating potential therapeutic efficacy.
CDKN2A and CDKN2B chromosomal abnormalities are being targeted, with CDKN2A gene deletions present in several solid tumors like bladder, breast, lung, pancreatic cancer, and certain T-cell lymphomas.
Initial clinical activity from the Phase 2 part of the study is expected to be reported starting in the fourth quarter of 2024.
Enrollment in the Fadra Phase 2 proof-of-concept study is progressing well, and initial results from around a dozen patients are anticipated by the end of 2024.
A second cohort targeting patients with T-cell lymphoma has been opened based on encouraging Phase 1 results, including partial responses observed in this specific subgroup.
Patients treated with Fadra showed good tolerance and compliance at the selected dose level five of 100 milligrams twice daily, five days a week, four out of four weeks, with no drug-related serious adverse events reported.
Several patients across different cancer types, such as T-cell lymphoma, non-small cell lung cancer, endometrial, ovarian, and pancreatic cancer, showed clinical benefit or partial responses to Fadra.
Financially, the company has strengthened with cash equivalents totaling $6 million as of June 30, 2024, compared to $3.4 million at the end of 2023.
Net cash used in operating activities has decreased significantly, with $3.6 million for the first half of 2024 compared to $8.2 million for the same period in 2023.
Net cash provided by financing activities was $6.3 million for the first half of 2024, reinforcing the company's financial position.
The current cash resources are estimated to fund planned programs into the fourth quarter of 2024, indicating financial stability and support for ongoing research and development efforts.
Negative
- The company's cash equivalents only totaled $6 million as of June 30, 2024, which may not be sufficient to fund planned programs beyond the fourth quarter of 2024.
- Net cash used in operating activities was $3.6 million for the six months ended June 30, 2024, indicating ongoing cash burn.
- A total of 25 drug-related serious adverse events (SAEs) were reported in eight patients during the evaluation of Fadra, including hyperglycemia, platelet count decrease, and accidental overdose.
CYCC FAQs
How does CYCC typically perform around its earnings report dates?
Is Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CYCC Earning Call Sentiment
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
CYCC.O
0.69%Positive
The earnings report shows positive signs such as reduced R&D expenses, net loss, and increased cash position. However, risks like limited cash resources beyond Q4 2024, decreased UK R&D tax credits, and competitive pressures balance these positives. The Q&A session revealed unclear management responses, adding to uncertainties. Given these mixed signals, the stock price is expected to remain neutral in the short term.